dievini Hopp BioTech holding GmbH & Co. KG
  • Welcome
  • Management
    • Dr. Friedrich von Bohlen
    • Prof. Dr. Christof Hettich
    • Dr. Mathias Hothum
  • Portfolio
  • News
  • Imprint
  • Data Protection
  • Deutsch
dievini Hopp BioTech holding GmbH & Co. KG
  • Welcome
  • Management
    • Dr. Friedrich von Bohlen
    • Prof. Dr. Christof Hettich
    • Dr. Mathias Hothum
  • Portfolio
  • News
  • Imprint
  • Data Protection
  • Deutsch

May 31, 2022: AC Immune SA

AC Immune to Present at the 2022 Jefferies Healthcare Conference

AC Immune SA, a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that company management will participate in a fireside chat and one-on-one investor meetings during the 2022 Jefferies Healthcare Conference, which is taking place in New York, NY from June 8-10, 2022.

Please read the whole article here
AC Immune SA, News 2022

May 27, 2022: Cosmo Pharmaceuticals NV

Cosmo Pharmaceuticals’ Shareholders approve all Agenda Items at Annual General Meeting

Cosmo Pharmaceuticals N.V. today announced that its shareholders approved all agenda items at today’s virtual annual general meeting of shareholders.

Please read the whole article here

Cosmo Pharmaceuticals NV, News 2022

May 25, 2022: CureVac AG

CureVac Partners with myNEO to Identify Novel Antigen Targets for mRNA-Based Cancer Vaccine Development

  • CureVac is broadening its foundation in oncology, leveraging recent progress with its second-generation mRNA backbone
  • The partnership combines CureVac’s mRNA technology with myNEO’s platform for the discovery and selection of tumor antigens predicted to elicit strong immune responses
  • Together with myNEO, CureVac aims to identify specific antigens for the development of novel mRNA cancer vaccines

CureVac N.V., a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), and myNEO N.V., a Belgium-based immunotherapy company, today announced that they have entered into a research and option agreement. Under the agreement, both companies aim to identify specific antigens found on the surface of tumors for the development of novel mRNA immunotherapies. To achieve this goal, myNEO will leverage its biological datasets and its integrated machine learning and bioinformatics platform to identify and validate specific antigen targets predicted to elicit a strong immune response.

Please read the whole article here

CureVac AG, News 2022

May 25, 2022: CureVac AG

CureVac Announces Financial Results for the First Quarter of 2022 and Provides Business Update

  • Progressing broad vaccine development program in collaboration with GSK, with second-generation candidates in Phase 1 clinical trials for COVID-19 and influenza
    • CureVac eligible to a €10 million milestone payment from GSK for the initiation of the influenza clinical trial
  • Increasing momentum in oncology with access to neoantigen technologies to feed meaningful pipeline of cancer vaccine candidates
    • Partnership with myNEO to develop novel mRNA cancer vaccines leveraging myNEO’s advanced platform for tumor antigen discovery and selection
  • Cash position of €658.2 million as of March 31, 2022, impacted by wind-down costs for first-generation COVID-19 vaccine program

CureVac N.V., a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced financial results for the first quarter of 2022 and provided a business update.

Please read the whole article here

CureVac AG, News 2022

May 18, 2022: Immatics Biotechnologies GmbH

Immatics Announces First Patient Treated with ACTengine® IMA203 TCR-T in Combination with Checkpoint Inhibitor Opdivo® (nivolumab) in Patients with Advanced Solid Tumors

  • The Phase 1b dose expansion cohort will evaluate safety, biological activity and initial anti-tumor activity of IMA203 TCR-T targeting PRAME in combination with nivolumab1, a PD-1 immune checkpoint inhibitor, in patients with multiple solid tumors
  • Initiation of the combination treatment follows positive interim results from the IMA203 monotherapy Phase 1a dose escalation cohort and determination of provisional recommended phase 2 dose
  • IMA203 targets an HLA-A*02-presented peptide derived from the protein PRAME that is highly prevalent and homogenously expressed at high target copy numbers across several solid cancer indications
  • IMA203 and nivolumab combination is part of Immatics’ strategy to realize the full clinical potential of IMA203 TCR-T targeting PRAME; initial data read-out is planned for YE 2022

Immatics N.V. (“Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today announced that the first patient has been dosed in the IMA203 and nivolumab combination Phase 1b dose expansion cohort. This cohort will evaluate Immatics’ TCR-engineered cell therapy (TCR-T) approach ACTengine® IMA203 targeting an HLA-A*02-presented peptide derived from PRAME, in combination with Bristol Myers Squibb’s PD-1 checkpoint inhibitor nivolumab, in patients with advanced solid tumors. The objectives of the study will be to evaluate the safety, biological activity, and initial anti-tumor activity of the IMA203 and nivolumab combination.

Please read the whole article here

Immatics Biotechnologies GmbH, News 2022

May 17, 2022: AC Immune SA

AC Immune CEO Andrea Pfeifer Receives Aenne Burda Award

neurodegenerative diseases, today announced that Dr. Andrea Pfeifer, CEO and a Director of AC Immune, will be awarded the prestigious Aenne Burda Award for Creative Leadership at the 22nd DLD Conference to be held in Munich, Germany, May 20-22, 2022.

Please read the whole article here

AC Immune SA, News 2022

May 10, 2022: Immatics Biotechnologies GmbH

Immatics Initiates Phase 1 Clinical Trial to Evaluate Lead TCR Bispecific IMA401 in Patients with Advanced Solid Tumors

  • Patient enrollment for IMA401 Phase 1 trial started at first clinical site in Germany
  • The study will evaluate safety, tolerability, and initial anti-tumor activity of IMA401 in patients with recurrent and/or refractory solid tumors
  • TCER® IMA401 targets MAGEA4/8 and will be developed in collaboration with Bristol Myers Squibb

Immatics N.V. (“Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today announced the initiation of a Phase 1 clinical trial with its T cell engaging receptor (TCER®) IMA401 for patients with recurrent and/or refractory solid tumors. IMA401 is the most advanced product candidate from Immatics’ TCR Bispecific pipeline targeting an HLA-A*02-presented peptide derived from both MAGEA4 and MAGEA8. TCER® IMA401 will be developed in collaboration with Bristol Myers Squibb. Immatics is responsible for conducting the Phase 1 clinical trial.

Please read the whole article here

Immatics Biotechnologies GmbH, News 2022

May 9, 2022: AC Immune SA

AC Immune’s Anti-Abeta Vaccine Results from Phase 1b Study in Down Syndrome Published in JAMA Neurology

First study of an anti-Abeta vaccine in people living with Down syndrome (DS)

Immune response and Alzheimer’s disease (AD) biomarkers showed positive impact of ACI-24 first generation vaccine

Optimized formulation of the ACI-24 vaccine to enter Phase 1b/2 testing this year

AC Immune SA, a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced the publication in JAMA Neurology1 of data showing that AC Immune’s ACI-24 anti-Abeta vaccine was found to be safe and elicited immune response in a Phase 1b clinical trial in adults with DS. This is the first anti-Abeta vaccine study conducted with people living with DS.

Please read the whole article here

AC Immune SA, News 2022

May 9, 2022: Heidelberg Pharma AG

Heidelberg Pharma AG and Partner Huadong Receive all Approvals for the Announced Transaction from the Authorities and Plan Capital Measure

As of 27th February 2022, Heidelberg Pharma and Huadong Medicine Co., Ltd., Hangzhou, China, (Huadong) have entered into a strategic partnership with the signing of an exclusive licensing agreement as well as an investment agreement regarding an equity investment in Heidelberg Pharma. The investment by Huadong is planned in August 2022 totaling EUR 105 million, representing 35% of outstanding shares after the transaction, consisting of a rights issue and a share transfer.

Please read the whole article here
Heidelberg Pharma AG, News 2022

May 3, 2022: Cosmo Pharmaceuticals NV

COSMO ANNOUNCES EXPANDING THE AGREEMENT WITH MEDTRONIC FOR ELEVIEW® TO ALL COUNTRIES EXCEPT CANADA

Cosmo Pharmaceuticals N.V. (“Cosmo”) announces the expansion of the agreement with Medtronic for the distribution of Eleview® to all countries except Canada, following the mutual termination of the license agreement with EA Pharma.

Please read the whole article here

Cosmo Pharmaceuticals NV, News 2022
Newer Entries
Older Entries
  • News 2022
  • News 2021
  • News 2020
  • News 2019
  • News 2018
  • General
  • Company
    • AC Immune SA
    • Apogenix AG
    • Cosmo Pharmaceuticals NV
    • CureVac AG
    • Heidelberg Pharma AG
    • Immatics Biotechnologies GmbH
    • Joimax GmbH
    • Molecular Health GmbH
    • Novaliq GmbH

dievini Hopp BioTech holding GmbH & Co. KG | Impressum | Datenschutz